More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy – By Roots Analysis

 

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

 

Key Inclusions

• A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue  placenta, peripheral blood, stromal cells  and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. In addition, information on the various technology platforms being actively used for the development of stem cell therapies has been provided.

 

• Identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas).

 

Detailed profiles of the key industry players engaged in the development of stem cell-based therapies, featuring a brief overview of the company (such as year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available)), details of their respective product portfolio and an informed future outlook

 

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

• Source of stem cell
• Allogeneic
• Autologous

 

• Origin of stem cell
• Adult
• Embryonic

 

• Type of stem cell
• Hematopoietic
• Mesenchymal
• Progenitor
• Others

 

• Lineage of stem cell
• Adipose Tissue
• Bone Marrow
• Cord Blood
• Others

 

• Route of Administration
• Intraarticular
• Intracoronary
• Intramuscular
• Intramyocardial
• Intrathecal
• Intravenous
• Surgical Implantations
• Others

 

• Therapeutic Area
• Autoimmune / Inflammatory Disorder
• Cardiovascular Disorders
• Metabolic Disorder
• Musculoskeletal Disorders
• Oncological Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Others

 

• End Users
• Ambulatory Surgery Centers
• Hospitals
• Specialty Clinics

 

• Key Geographies
• North America
• Europe
• Asia-Pacific and Rest of the World

 

The Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. report features the following companies, which we identified to be key players in this domain:

• Anterogen
• Athersys
• CHABiotech
• Cytopeutics
• Hope Biosciences
• Japan Regenerative Medicine
• Lineage Cell Therapeutics
• Orchard Therapeutics
• Osiris Therapeutics
• Pluristem Therapeutics
• Promithera Biosciences
• Regenexx
• Stempeutics Research
• SCM Life Sciences
• TICEBA

 

Table of Contents

 

1. Preface
   
   2. Executive Summary
2. 
   Introduction
    
3. Market Landscape
    
4. Company Profiles
    
5. Key Therapeutic Areas
    
6. Assessment of Relative Competition and Growth Opportunities
    
7. Academic Grants Analysis
    
8. Clinical Trail Analysis
    
9. Stem Cell Manufacturing Market Landscape and KPIs for Evaluating Contract

Services Partners
 

1. Stem Cell Therapy Developers and CMOs: Opportunity Assessment
    
2. Key Commercialization Strategies

 

1. Market Forecast
    
2. Conclusion
    
3. Executive Insights

 

1. Appendix 1: Tabulated Data

 

1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]